Last updated: August 10, 2026
Aldactone is the branded form of spironolactone, a mature potassium-sparing diuretic and mineralocorticoid receptor antagonist. Its commercial value now comes primarily from a large generic spironolactone market rather than from branded sales. The product has no meaningful remaining regulatory exclusivity, no material patent barrier to generic entry, and limited standalone financial disclosure from Pfizer. Demand remains durable because spironolactone is used across heart failure, hypertension, edema, hyperaldosteronism and several common off-label dermatology indications.
What is Aldactone and how is spironolactone used?
Aldactone contains spironolactone, a competitive antagonist of aldosterone at the mineralocorticoid receptor. It also has antiandrogenic activity, which supports off-label use in acne, hirsutism and androgen-related disorders.
The FDA-approved indications include:
- Edema associated with congestive heart failure, cirrhosis and nephrotic syndrome
- Treatment of essential hypertension
- Diagnosis and treatment of primary hyperaldosteronism
- Adjunctive treatment for heart failure with reduced ejection fraction
- Reduction of potassium loss in selected patients
The product is available in multiple tablet strengths, including 25 mg, 50 mg and 100 mg. Generic spironolactone is widely available in additional strengths and dosage configurations depending on the manufacturer.
The principal clinical constraint is hyperkalemia. Renal impairment, diabetes, older age and concurrent use of ACE inhibitors, angiotensin receptor blockers, potassium supplements or other potassium-sparing agents increase monitoring requirements. Gynecomastia, menstrual irregularities and sexual adverse effects also affect persistence, particularly in male patients.
When did Aldactone lose exclusivity?
Aldactone lost practical market exclusivity decades ago. Spironolactone is a legacy small-molecule product, and generic versions are widely approved and sold in the United States.
| Milestone |
Status |
| Active ingredient |
Spironolactone |
| Original U.S. approval |
1960 |
| Brand |
Aldactone |
| Current U.S. brand holder |
Pfizer group company, through Pharmacia & Upjohn labeling |
| Regulatory exclusivity |
Expired |
| Patent-based generic barrier |
No material current barrier identified |
| Generic availability |
Broad, with multiple approved manufacturers |
| Biosimilar exposure |
None; Aldactone is a small molecule, not a biologic |
FDA drug labeling identifies Aldactone as a long-established product marketed by Pharmacia & Upjohn, a Pfizer company.[1] FDA’s Orange Book provides the regulatory framework for listed patents and exclusivity, but Aldactone’s commercial position is no longer protected by an active new-drug exclusivity period.[2]
What patents protect Aldactone?
No commercially meaningful Aldactone patent estate remains in the United States. The original composition-of-matter and product patents expired long ago. The active ingredient is well understood, chemically simple and manufactured by multiple generic suppliers.
Current intellectual-property protection is more relevant to individual manufacturers than to Aldactone itself. Potentially relevant rights may include:
- Manufacturing-process patents for particular intermediates or purification methods
- Formulation patents for modified-release or combination products
- Packaging or device patents
- Method-of-use patents for narrowly defined patient populations
- Foreign patents with different expiration dates
Those rights do not recreate the exclusivity associated with the original Aldactone product. Immediate-release spironolactone tablets are a mature generic category with low switching costs for pharmacies and payers.
Does Aldactone have Orange Book-listed patents?
Aldactone does not have a meaningful current Orange Book patent position comparable with a recently launched branded drug. The Orange Book remains the primary U.S. source for listed patents, pediatric exclusivity and other regulatory information.[2]
Because generic spironolactone products are already marketed, a new Paragraph IV challenge to the original Aldactone product would have little commercial significance. The relevant competitive event occurred when generic manufacturers entered the market, not when a future challenger might contest an obsolete patent.
Are there Paragraph IV challenges to Aldactone?
Paragraph IV litigation is not a current commercial driver for Aldactone. Paragraph IV certifications apply when an ANDA applicant asserts that a listed patent is invalid, unenforceable or will not be infringed. A mature product with expired patents and existing generic supply generally does not produce a meaningful new Paragraph IV cycle.
The competitive risks instead involve:
- Approval or launch of additional generic suppliers
- FDA inspections and manufacturing interruptions
- Active pharmaceutical ingredient shortages
- Retail and hospital contracting
- Formulary substitution
- Pricing pressure among generic manufacturers
No major current Paragraph IV dispute is central to Aldactone’s U.S. market outlook based on the product’s mature regulatory status.
What is the FDA regulatory status of Aldactone?
Aldactone remains an FDA-approved prescription product. Its clinical positioning is supported by longstanding labeling and by evidence supporting mineralocorticoid receptor antagonism in heart failure.
The regulatory profile is stable but operationally demanding:
| Regulatory factor |
Commercial effect |
| Approved prescription product |
Supports continued use in labeled indications |
| Generic substitution |
Reduces brand pricing power |
| Hyperkalemia warning |
Requires laboratory monitoring |
| Renal impairment restrictions |
Limits use in some patients |
| No biologic component |
Eliminates biosimilar substitution issues |
| Multiple generic suppliers |
Improves availability but compresses price |
Spironolactone’s role in heart failure is supported by guideline-directed medical therapy. The 2022 AHA/ACC/HFSA heart failure guideline recommends mineralocorticoid receptor antagonist therapy for appropriate patients with reduced ejection fraction, provided renal function and potassium levels meet safety criteria.[3]
How large is the Aldactone and spironolactone market?
The market should be divided into three segments:
- Branded Aldactone sales
- Generic spironolactone prescription volume
- Off-label and specialty demand, particularly dermatology and endocrine care
Generic spironolactone represents the economically significant segment. Public company filings generally do not report spironolactone revenue separately because the product is bundled within broader established-product or generic portfolios. Pfizer reports at segment and product-group levels, not as a standalone Aldactone revenue line.[4]
This limits the reliability of headline market-size estimates. Prescription volume, claims data and wholesaler sales are more useful than reported brand revenue for evaluating demand.
What drives spironolactone demand?
Demand is supported by several independent treatment markets:
- Heart failure, particularly reduced ejection fraction
- Resistant hypertension
- Primary hyperaldosteronism
- Cirrhosis-associated ascites
- Nephrotic and other edema states
- Acne and hirsutism
- Gender-affirming and antiandrogen therapy in selected clinical settings
The most durable demand comes from cardiovascular and endocrine use. Dermatology creates substantial additional volume but is more exposed to practice patterns, telehealth prescribing and changing treatment preferences.
Growth is likely to be volume-led rather than price-led. Generic prices tend to decline as suppliers compete, while patient volume can rise through broader guideline adoption and increased diagnosis of resistant hypertension and heart failure.
What is Aldactone’s financial trajectory?
Aldactone’s financial trajectory has four phases:
| Period |
Financial profile |
| Launch and protected period |
Brand pricing and margin supported by exclusivity |
| Post-generic entry |
Rapid erosion of branded volume and price |
| Mature generic period |
High prescription volume with low unit economics |
| Current market |
Stable, low-growth category with occasional supply-driven pricing |
Pfizer’s current financial reporting does not identify Aldactone as a material standalone revenue contributor. The brand’s economic value is therefore likely limited relative to Pfizer’s newer patented medicines and vaccines. Pfizer’s established-products portfolio is exposed to generic competition, price controls, purchasing consolidation and product rationalization.[4]
The generic market has a different financial structure. Manufacturers compete on:
- Cost of active pharmaceutical ingredient
- Tablet production efficiency
- FDA compliance
- Wholesaler access
- Pharmacy benefit manager contracts
- Supply reliability
- Ability to maintain multiple strengths
A supplier may accept low margins to preserve manufacturing utilization or portfolio access. A shortage or plant disruption can temporarily increase prices, but such increases are usually unstable when alternative suppliers remain approved.
How does Aldactone compare with competing drugs?
Spironolactone versus eplerenone
Eplerenone is a more selective mineralocorticoid receptor antagonist. It generally causes fewer antiandrogenic adverse effects but is more expensive and may require stronger payer justification. Spironolactone remains the lower-cost option in many cardiovascular and hypertension settings.
Spironolactone versus finerenone
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist approved for reducing risks associated with chronic kidney disease and type 2 diabetes. Its differentiated clinical positioning and branded pricing create a stronger commercial profile, but its label is narrower than the broad historical use of spironolactone.[5]
Spironolactone versus amiloride
Amiloride is another potassium-sparing diuretic. It does not have the same mineralocorticoid receptor antagonist profile and is generally less prominent in heart failure treatment. It competes more directly in selected hypertension and electrolyte-management situations.
Spironolactone versus loop and thiazide diuretics
Loop and thiazide diuretics remain important for volume management and blood-pressure control. They are often used in combination with spironolactone, so their relationship is frequently complementary rather than directly substitutive.
What formulation patents protect spironolactone?
Immediate-release spironolactone tablets are weakly differentiated products. The main barriers to entry are formulation execution, bioequivalence, manufacturing quality and supply reliability rather than proprietary science.
Potentially differentiated formulations could include:
- Modified-release tablets
- Liquid or suspension formulations
- Pediatric dosage forms
- Combination products
- Topical preparations
- Abuse-resistant or adherence-focused presentations
These products may support separate intellectual-property strategies, but they do not materially protect conventional Aldactone tablets. A new formulation would also need to demonstrate clinical or commercial value against a low-cost generic reference product.
What patent litigation affects Aldactone?
No major current patent litigation appears to determine the commercial trajectory of conventional Aldactone in the United States. The product is outside the normal litigation cycle for newly approved small molecules.
Future legal activity would be more likely to involve:
- A newly developed spironolactone formulation
- A fixed-dose combination
- A narrow method-of-use claim
- Manufacturing-process disputes
- ANDA litigation involving a new branded reformulation
Such disputes would affect a specific product or manufacturer, not the established generic market as a whole.
Which companies are challenging Aldactone?
The market is challenged by a broad field of generic manufacturers rather than by one dominant Paragraph IV challenger. U.S. generic spironolactone supply has historically included large generic companies and contract manufacturers such as Teva, Viatris, Sandoz, Hikma and multiple private-label suppliers, subject to product-specific FDA approvals and commercial availability.
The relevant competitive question is supplier concentration. A product may have many approved ANDAs but fewer active suppliers at the wholesaler or pharmacy level. That distinction matters during manufacturing disruptions, recalls or API shortages.
What generic entry risks exist for Aldactone?
Generic entry risk is effectively realized rather than prospective. Brand Aldactone faces:
- Persistent substitution by lower-priced generics
- Low prescriber sensitivity to brand selection
- Payer preference for generic spironolactone
- Limited switching friction between tablet suppliers
- Weak ability to raise prices without losing volume
Generic manufacturers face a different risk profile:
- FDA warning letters or manufacturing remediation
- Product recalls
- Potassium-related labeling and safety exposure
- API supply disruption
- Contract loss to larger suppliers
- Margin compression from additional entrants
The absence of patent barriers means supply, compliance and cost position determine market share.
What is the geographic coverage of Aldactone protection?
Aldactone’s original protection has expired in major pharmaceutical markets. Current commercial rights are primarily trademark, regulatory-label and distribution rights rather than blocking patent rights.
Patent and regulatory positions differ by country, but the strategic conclusion is consistent:
- North America: mature generic competition
- Europe: mature generic and parallel-distribution markets
- Japan: established generic substitution
- Emerging markets: local registration, manufacturing and distribution determine access
Geographic revenue is difficult to isolate because Pfizer does not publicly break out Aldactone sales by country. Local pricing can differ substantially because of national reimbursement systems and procurement rules.
What is the outlook for Aldactone revenue?
The branded revenue outlook is low-growth to declining unless the product benefits from a supply disruption, a temporary channel change or a niche brand-prescribing strategy. Generic spironolactone volume has a more stable outlook.
The most probable trajectory is:
- Stable or modestly growing prescription volume
- Continued unit-price pressure
- Minimal contribution from branded Aldactone
- Ongoing demand from heart failure and resistant hypertension
- Incremental growth from dermatology and endocrine prescribing
- Periodic volatility tied to manufacturing and procurement
Aldactone is therefore a clinically durable but commercially mature asset. Its value lies in recurring demand and broad clinical utility, not in patent leverage, premium pricing or litigation protection.
Key Takeaways
- Aldactone is the original branded spironolactone product and is marketed in the United States through Pfizer’s Pharmacia & Upjohn organization.
- The product has lost regulatory exclusivity and faces extensive generic substitution.
- No current patent estate materially protects conventional Aldactone tablets.
- Paragraph IV litigation is not a major current market driver.
- Generic spironolactone generates the meaningful market volume, while branded Aldactone revenue is not separately disclosed by Pfizer.
- Demand is supported by heart failure, resistant hypertension, hyperaldosteronism, edema and off-label dermatology use.
- Eplerenone and finerenone compete on selectivity, safety profile and differentiated clinical positioning.
- The financial outlook is stable in volume but weak in pricing, with supply reliability and manufacturing quality determining generic profitability.
FAQs
Is Aldactone still sold under the Pfizer brand?
Yes. Aldactone remains an FDA-approved branded spironolactone product associated with Pharmacia & Upjohn, a Pfizer company, while generic spironolactone is widely available.
Is spironolactone a biologic or does it face biosimilar competition?
No. Spironolactone is a synthetic small-molecule drug. It faces ordinary generic competition under the ANDA pathway, not biosimilar competition under the Biologics Price Competition and Innovation Act.
Can a new spironolactone formulation obtain patent protection?
Yes. A novel formulation, delivery system, combination product or manufacturing process may qualify for patent protection if it meets patentability requirements. That protection would apply to the new product, not to conventional Aldactone tablets.
Why does spironolactone remain widely used despite generic price erosion?
Its clinical utility is broad, its cost is low, and guideline-supported use in appropriate heart-failure patients creates recurring demand. It also has established roles in resistant hypertension, endocrine disease and dermatology.
What is the main investment risk in the spironolactone market?
The main risk is margin compression in a mature generic category. Secondary risks include manufacturing interruptions, API concentration, regulatory remediation and safety-related restrictions involving hyperkalemia.
References
-
Pfizer Inc. (n.d.). Aldactone (spironolactone) tablets prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fed rip? 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation, 145(18), e895-e1032. https://doi.org/10.1161/CIR.0000000000001063
-
Pfizer Inc. (2024). Annual report 2023. https://www.pfizer.com/investors/financial-reports/annual-reports
-
U.S. Food and Drug Administration. (2021). Kerendia (finerenone) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf
